IDH1 and astrocytoma (excluding glioblastoma): As confirmed in a subsequent genomic analysis of the trial, survival benefit was observed in patients with either IDH-mutant astrocytoma or oligodendroglioma but not in those with IDH-wild-type tumor [6].